Amicus' Q3 Earnings Beat, Higher Product Sales Drive Y/Y Revenues

Key Takeaways Amicus posted adjusted Q3 earnings of $0.17 per share, which beat the consensus estimate of $0.12.Revenues grew 19% to $169.1 million, driven by higher Galafold and Pombiliti Opfolda product sales.FOLD reaffirmed 2025 guidance, projecting 15-22% CER revenue growth and positive GAAP net income.Amicus Therapeutics (FOLD) reported adjusted earnings of 17 cents per share for the third quarter of 2025, which beat the Zacks Consensus Estimate of 12 cents. The company had reported adjusted earnings o ...